Asset Details
Do you wish to reserve the book?
Acute paronychia and reactive capillary proliferation in a patient on erlotinib
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Acute paronychia and reactive capillary proliferation in a patient on erlotinib
Do you wish to request the book?
Acute paronychia and reactive capillary proliferation in a patient on erlotinib
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Acute paronychia and reactive capillary proliferation in a patient on erlotinib
2020
Overview
Sir, Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor which targets epidermal growth and metastasis in solid cancers such as lung, pancreas, breast, and gastrointestinal tract. On examination, left great toe revealed an ill-defined tender, erythematous swelling in the periungual region with a well-defined vascular growth at the junction of proximal and lateral nail folds with bloody discharge, suggestive of pyogenic granuloma. {Figure 1}{Figure 2} EGFR inhibitors including small molecule tyrosine kinase inhibitors (erlotinib and gefitinib) and their chimeric monoclonal antibody (cetuximab) are increasingly been used in the management of various solid malignancies, such as non-small cell lung cancer and pancreatic cancer.
Publisher
Wolters Kluwer India Pvt. Ltd,Medknow Publications & Media Pvt. Ltd,Wolters Kluwer - Medknow,Wolters Kluwer Medknow Publications
